Intron a and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Intron a (interferon alfa-2b), especially for people who are male, 40-49 old, have been taking the drug for 1 - 6 months also take Rebetol, and have Hepatitis c.

The phase IV clinical study analyzes which people have Hearing loss when taking Intron a. It is created by eHealthMe based on reports of 9,303 people who have side effects when taking Intron a from the FDA, and is updated regularly.

What is Intron a?

Intron a has active ingredients of interferon alfa-2b. eHealthMe is studying from 9,320 Intron a users. Check the latest studies of Intron a.

What is Hearing loss?

Hearing loss is found to be associated with 1,358 drugs and 2,388 conditions by eHealthMe. Check the latest studies of Hearing loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

9,303 people reported to have side effects when taking Intron a.
Among them, 54 people (0.58%) have Hearing loss.

Among these 54 people:

How long have people been on Intron a when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Intron a? *

female: 23.53 %
male: 76.47 %

What is the age of people who have Hearing loss when taking Intron a? *

What are other drugs people take besides Intron a? *

What are other side effects people have besides Hearing loss? *

Tinnitus (a ringing in the ears): 10 people, 18.52%
Hypoaesthesia (reduced sense of touch or sensation): 4 people, 7.41%
Weight Decreased: 4 people, 7.41%
Hearing Impaired: 3 people, 5.56%
Fall: 3 people, 5.56%
Thrombocytopenia (decrease of platelets in blood): 3 people, 5.56%
Hair Color Changes: 2 people, 3.70%
Blood Lactic Acid Increased: 2 people, 3.70%
Hemiparesis (weakness on one side of the body): 2 people, 3.70%
C-Reactive Protein Increased: 2 people, 3.70%

What are the existing conditions these people have? *

Hepatitis C: 9 people, 16.67%
Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 2 people, 3.70%
Lipids Increased (excess lipid in body): 2 people, 3.70%
Malignant Melanoma Site/stage Unspecified (cancer of skin un specific stage): 1 person, 1.85%
Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 1 person, 1.85%

* Approximation only. Some reports may have incomplete information.

Do you take Intron a and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Intron a:

Intron a (9,320 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Intron a:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,358 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,388 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on interferon alfa-2b (the active ingredients of Intron a) and Intron a (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.